These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31877948)

  • 1. Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.
    Dratkiewicz E; Simiczyjew A; Pietraszek-Gremplewicz K; Mazurkiewicz J; Nowak D
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
    Girotti MR; Pedersen M; Sanchez-Laorden B; Viros A; Turajlic S; Niculescu-Duvaz D; Zambon A; Sinclair J; Hayes A; Gore M; Lorigan P; Springer C; Larkin J; Jorgensen C; Marais R
    Cancer Discov; 2013 Feb; 3(2):158-67. PubMed ID: 23242808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression.
    Molnár E; Garay T; Donia M; Baranyi M; Rittler D; Berger W; Tímár J; Grusch M; Hegedűs B
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
    Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
    Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.
    Laurenzana A; Margheri F; Biagioni A; Chillà A; Pimpinelli N; Ruzzolini J; Peppicelli S; Andreucci E; Calorini L; Serratì S; Del Rosso M; Fibbi G
    EBioMedicine; 2019 Jan; 39():194-206. PubMed ID: 30611716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
    Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
    Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
    Carroll MJ; Parent CR; Page D; Kreeger PK
    BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
    Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
    Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
    Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
    Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.
    Ng YK; Lee JY; Supko KM; Khan A; Torres SM; Berwick M; Ho J; Kirkwood JM; Siegfried JM; Stabile LP
    Melanoma Res; 2014 Jun; 24(3):207-18. PubMed ID: 24709886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
    Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
    Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma.
    Park BS; Jeon H; Kim Y; Kwon H; Choi GE; Chi SG; Park HM; Lee H; Kim T
    Mol Cancer; 2024 Jul; 23(1):136. PubMed ID: 38965534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.
    Pietrantonio F; Oddo D; Gloghini A; Valtorta E; Berenato R; Barault L; Caporale M; Busico A; Morano F; Gualeni AV; Alessi A; Siravegna G; Perrone F; Di Bartolomeo M; Bardelli A; de Braud F; Di Nicolantonio F
    Cancer Discov; 2016 Sep; 6(9):963-71. PubMed ID: 27325282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
    Straussman R; Morikawa T; Shee K; Barzily-Rokni M; Qian ZR; Du J; Davis A; Mongare MM; Gould J; Frederick DT; Cooper ZA; Chapman PB; Solit DB; Ribas A; Lo RS; Flaherty KT; Ogino S; Wargo JA; Golub TR
    Nature; 2012 Jul; 487(7408):500-4. PubMed ID: 22763439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.
    Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
    Exp Cell Res; 2020 May; 390(2):111942. PubMed ID: 32173467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

  • 18. Acquisition of resistance to vemurafenib leads to interleukin-10 production through an aberrant activation of Akt in a melanoma cell line.
    Inozume T; Tsunoda T; Morisaki T; Harada K; Shirasawa S; Kawamura T
    J Dermatol; 2018 Dec; 45(12):1434-1439. PubMed ID: 30222203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.
    Delgado-Goñi T; Galobart TC; Wantuch S; Normantaite D; Leach MO; Whittaker SR; Beloueche-Babari M
    Br J Cancer; 2020 Jan; 122(1):72-81. PubMed ID: 31819183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.